SCHEMBL24329751

SCHEMBL24329751

CC(C)(C)OC(=O)N1CCC(c2cccc(OCc3ccc(Br)cc3F)n2)CC1

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GLP1R P43220 18/20 0.48
TRPV3 Q8NET8 1/20 0.47
DPP4 P27487 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24485767 0.91 GLP1R (0.56) GLP1RTRPV3
SCHEMBL29668702 0.91 GLP1R (0.56) GLP1RTRPV3
SCHEMBL24321925 0.90 GLP1R (0.48) GLP1RTRPV3
SCHEMBL24329499 0.90 GLP1R (0.45) GLP1RTRPV3
SCHEMBL24330224 0.90 TRPV3 (0.49) GLP1RTRPV3DPP4
SCHEMBL29668681 0.90 GLP1R (0.58) GLP1R
SCHEMBL20266522 0.90 GLP1R (0.58) GLP1R
SCHEMBL24329490 0.90 GLP1R (0.48) GLP1RTRPV3
SCHEMBL24329496 0.89 GLP1R (0.55) GLP1R
SCHEMBL24329293 0.89 GLP1R (0.58) GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US disclosed
US-20240246959-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2024-07-25 US disclosed
CN-115461334-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-21 CN disclosed
EP-4242202-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) 2023-09-13 EP disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
CN-116348464-A Benzimidazolone GLP-1 receptor agonists and uses thereof 杭州中美华东制药有限公司 2023-06-27 CN disclosed
CN-115461334-A Benzimidazole derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-12-09 CN disclosed
WO-2022111624-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2022-06-02 WO disclosed
WO-2022111624-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2022-06-02 WO disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF GLP1R, GIPR, GCGR GLP1R 1/4885TRPV3 316/4885DPP4 39/4885
US-20240246959-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GLP1R, GIPR, GCGR GLP1R 1/4885TRPV3 1149/4885DPP4 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.